QuidelOrtho (QDEL)
(Real Time Quote from BATS)
$42.99 USD
+0.49 (1.15%)
Updated May 6, 2024 03:24 PM ET
5-Strong Sell of 5 5
B Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
QDEL 42.99 +0.49(1.15%)
Will QDEL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QDEL
Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
Other News for QDEL
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Ligand Pharma (LGND) and Bioventus (BVS)
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
QuidelOrtho names Brian Blaser as CEO
What's Driving LivaNova PLC's Surprising 15% Stock Rally?
RBC Capital Remains a Buy on QuidelOrtho (QDEL)